GlassScriptPhysician profile
Bethany A Rich
NPI 1518348218
$3,683.91
in general payments reported to CMS, 2019-2025
24 companies · $2,892 in 2025
The $2,892 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $26.54 · 2024: $766 · 2025: $2,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,683.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $554.80 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $511.32 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $457.32 | 2024-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $403.86 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $214.75 | 2025 | Voquezna |
| Madrigal Pharmaceuticals | $152.92 | 2024-2025 | Rezdiffra, Resmetirom |
| Neuraxis, INC. | $146.32 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $132.64 | 2024-2025 | Dupixent |
| Gilead Sciences, INC. | $121.37 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $115.41 | 2024-2025 | |
| Ardelyx, INC. | $106.08 | 2024-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $104.79 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $83.94 | 2025 | Vowst |
| Genzyme Corporation | $83.06 | 2025 | |
| Lilly USA, LLC | $80.62 | 2024-2025 | Omvoh, Zepbound |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $67.17 | 2025 | Rebyota |
| Inspire Medical Systems, INC. | $66.64 | 2024-2025 | Inspire |
| Novo Nordisk INC | $60.27 | 2024-2025 | Wegovy, Saxenda |
| Alnylam Pharmaceuticals INC. | $57.89 | 2025 | Givlaari |
| Braintree Laboratories, INC. | $47.84 | 2024-2025 | Sutab, Suflave |
| Qol Medical, LLC | $32.59 | 2024 | Sucraid |
| Currax Pharmaceuticals LLC | $30.77 | 2024-2025 | Contrave |
| Glaxosmithkline, LLC. | $26.54 | 2023 | Arexvy, Shingrix |
| Pfizer INC. | $25.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Rich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.